Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

Summary

In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics.

Detailed Description

In this pivotal trial, we aim to perform a prospective study to find the efficacy of iPredict-DR, an artificial intelligence (AI) based software tool on early diagnosis of Diabetic Retinopathy (DR) in the primary care and endocrinology clinics. DR is one of the leading causes of blindness in the United States and other developed countries. Every individual with diabetes is at risk of DR. It does not show any symptoms until the disease is progressed to advanced stages. If the disease is caught at an early stage, it can be prevented, managed, or treated effectively. Currently, screening for DR is done by the Ophthalmologists, which is limited to areas with limited availability. This is also time-consuming and expensive. All of these can be complemented by automated screening and set up the screening in the primary care clinics. American Academy of Ophthalmology has suggested a 5-level DR disease severity scale (No DR, Mild DR, Moderate DR, Severe DR or Proliferative DR) based on the abnormalities in the retina such as microaneurysms, exudates, hemorrhages, intraretinal microvascular abnormalities (IRMA), and neovascularization. Automated screening for Diabetic Retinopathy has a potential to identify people at risk of developing sight-threatening disease and save millions of dollars in healthcare costs. To accomplish this, it is crucial to perform large scale population screening to identify the individuals with mild or early DR and better predict those at risk of developing late stage DR. A system that takes advantage of telemedicine with automated DR screening in reaching the mass populations in both urban and rural areas with the patient convenience is currently not widely available. Considering this urgent need, iHealthScreen has developed an automated software tool for DR screening which is based on artificial intelligence (AI) and make it widely available in both urban and remote/rural areas and for large-scale screening through a telemedicine platform, and thereby have the potential to prevent blindness in diabetic patients.

Eligibility Criteria

Interventions